Sonoma Pharmaceuticals, Inc.

NasdaqCM:SNOA Stock Report

Market Cap: US$5.6m

Sonoma Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SNOA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders20,1840.43%
Institutions108,9142.32%
General Public4,564,47897.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 191.2%.

Top Shareholders

Top 21 shareholders own 2.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
1.3%
DRW Holdings, LLC
60,977US$73.3k257%0.01%
0.4%
The Vanguard Group, Inc.
18,887US$22.7k-9.51%no data
0.34%
Geode Capital Management, LLC
15,908US$19.1k-9.7%no data
0.24%
McKinley Carter Wealth Services, Inc.
11,193US$13.5k0%no data
0.16%
Bruce Thornton
7,720US$9.3k0%no data
0.16%
Amy Trombly
7,679US$9.2k0%no data
0.09%
Jerome Dvonch
4,229US$5.1k0%no data
0.016%
Global Retirement Partners, LLC
772US$928.676.3%no data
0.011%
Osaic Wealth, Inc.
500US$601.20%no data
0.0082%
Tower Research Capital Europe Limited
385US$462.9-74.9%no data
0.0061%
Jay Birnbaum
286US$343.80%no data
0.0057%
John McLaughlin
270US$324.60%no data
0.0026%
JPMorgan Chase & Co.
121US$145.6-1.63%no data
0.0024%
BlackRock, Inc.
113US$136.10%no data
0.00053%
U.S. Bancorp Asset Management, Inc.
25US$29.90%no data
0.00038%
Bank of America Corporation
18US$21.55.88%no data
0.00013%
UBS Asset Management AG
6US$7.3-94.4%no data
0.00009%
Morgan Stanley
4US$5.10%no data
0.00006%
Quaker Wealth Management, LLC
3US$3.40%no data
0.00002%
Danske Capital AS (Estonia)
1US$1.10%no data
0.00002%
Carson Wealth Management Group
1US$1.10%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/04 00:14
End of Day Share Price 2026/05/04 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sonoma Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jack WallaceSidoti & Company, LLC
David LavigneTrickle Research